# Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

> **NCT04982224** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Advanced NSCLC

## Interventions

- **DRUG:** REGN5093-M114
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT04982224
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-09
- **Primary completion:** 2025-10-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982224, "Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04982224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*